These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Diagnostics and drug therapy of multiple sclerosis]. Suomen Neurologinen Yhdistys ry Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889 [No Abstract] [Full Text] [Related]
6. Immunosuppressive Treatments in Multiple Sclerosis. Proceedings of the European Charcot Foundation Symposium. Seville, Spain, 28-30 November 2002. J Neurol Sci; 2004 Aug; 223(1):1-93. PubMed ID: 15470812 [No Abstract] [Full Text] [Related]
7. New treatments for multiple sclerosis. Hutchinson M Ir Med J; 1996; 89(2):44. PubMed ID: 8682623 [No Abstract] [Full Text] [Related]
8. [Multiple sclerosis]. Itoyama Y No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536 [No Abstract] [Full Text] [Related]
9. [What's new in multiple sclerosis therapy?]. Vaney C; Derfuss T Rev Med Suisse; 2013 Jan; 9(371):285-7. PubMed ID: 23451607 [No Abstract] [Full Text] [Related]
10. New treatments for multiple sclerosis. Kilpatrick TJ; Soilu-Hänninen M Aust N Z J Med; 1999 Dec; 29(6):801-10. PubMed ID: 10677125 [No Abstract] [Full Text] [Related]
11. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
13. [Review of the therapy of multiple sclerosis]. De Rosa A; Puccini A; De Martino V Recenti Prog Med; 1982 Dec; 73(6):651-68. PubMed ID: 6308734 [No Abstract] [Full Text] [Related]
14. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept]. Kornhuber ME; Zierz S Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792 [No Abstract] [Full Text] [Related]
15. The current therapy of multiple sclerosis. Francis DA J Clin Pharm Ther; 1993 Apr; 18(2):77-84. PubMed ID: 8458884 [TBL] [Abstract][Full Text] [Related]
16. [Multiple sclerosis: beyong first line therapies]. Schluep M; Du Pasquier R Rev Med Suisse; 2012 May; 8(339):946-9. PubMed ID: 22675826 [TBL] [Abstract][Full Text] [Related]
17. [Clinical and MRI effects of Glatirameracetate]. Nervenarzt; 1999 Aug; 70(8 Suppl):1-8. PubMed ID: 10511871 [No Abstract] [Full Text] [Related]
18. [Current methods of the multiple sclerosis treatment]. Kovalenko PA; Shamanskiĭ SV; Baziĭ NI Voen Med Zh; 2001 Oct; 322(10):45-52. PubMed ID: 11764483 [No Abstract] [Full Text] [Related]
19. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis. Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092 [No Abstract] [Full Text] [Related]
20. Multiple sclerosis--a review. McLeod JG Aust N Z J Med; 1982 Aug; 12(4):302-8. PubMed ID: 6753817 [No Abstract] [Full Text] [Related] [Next] [New Search]